Cellectar Biosciences Stock: $140 Million Deal Puts Iopofosine FDA Filing in Focus
Cellectar Biosciences on Tuesday secured up to $140 million in new funding and rolled out fresh 12-month results for its iopofosine I 131 program, giving the cancer drug maker a shot of cash for a planned confirmatory trial and a potential U.S. submission in Waldenström macroglobulinemia. The company pegged the overall response rate at 83.6% from its Phase 2b CLOVER WaM trial, targeting this rare blood cancer.